Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary

On 2nd Sep'26, Remus Pharmaceuticals approved the migration of its shares from the NSE Emerge platform to the NSE and BSE Main Boards, pending shareholder

Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary

Remus Pharmaceuticals Ltd 路 Outcome 路 03 Sept 2026, 12:01 am

Remus Pharmaceuticals Approves Main Board Migration and New Dominican Republic Subsidiary On 2nd Sep'26, Remus Pharmaceuticals approved the migration of its shares from the NSE Emerge platform to the NSE and BSE Main Boards, pending shareholder and regulatory approvals. The Board also authorized forming a pharmaceutical supply and distribution subsidiary in the Dominican Republic, with Remus acquiring a 51% or greater equity stake via cash consideration. Additionally, experienced FMCG entrepreneur Ashutosh Naginbhai Valani was appointed as a Non-Executive Independent Director for a five-year term, effective immediately.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements